<DOC>
	<DOCNO>NCT02860819</DOCNO>
	<brief_summary>This proof-of-concept study define efficacy gemcitabine , carboplatin VELIPARIB ( ABT-888 ) patient refractory germ cell tumor ( GCTs ) . PARP proteins involve base excision repair ( BER ) , one major DNA repair system cell PARP overexpressed testicular GCTs ( TGCTs ) compare normal testis data suggest PARP overexpression early event TGCTs development . Patients low PARP expression primary tumour non-significantly well OS compare patient high PARP expression ( 5-year OS 89.2 % vs 78.7 % ; HR=0.50 , 95 % CI 0.21 1.17 , p=0.12 ) . The aim study evaluate PARP inhibitor VELIPARIB combination gemcitabine , carboplatin patient refractory germ cell tumor ( GCTs ) .</brief_summary>
	<brief_title>Study Gemcitabine , Carboplatin VELIPARIB ( ABT-888 ) Refractory Testicular Germ Cell Cancer</brief_title>
	<detailed_description>PARP proteins involve base excision repair ( BER ) , one major DNA repair system cell . Recently , show PARP inhibitor strike efficacy patient BRCA1 deficient triple negative breast cancer monotherapy combination cisplatin base chemotherapy , without increase systemic toxicity . Pertubations affect homologous recombination ( HR ) involve DNA repair associate high probability response PARP inhibitor . Inactivation PTEN , tumor suppressor protein , associate defect HR response PARP inhibitor . Recently , PARP expression evaluate TGCTs . It show PARP overexpressed testicular germ cell tumour compare normal testis PARP overexpression early event TGCTs development . Patients low PARP expression primary tumour non-significantly well OS compare patient high PARP expression ( 5-year OS 89.2 % vs 78.7 % ; HR=0.50 , 95 % CI 0.21 1.17 , p=0.12 ) .Loss tumor suppressor gene PTEN mark transition intratubular germ cell neoplasia ( ITGCN ) invasive germ cell tumor . In testis , PTEN abundantly express germ cell whereas virtually absent 56 % seminoma well 86 % embryonal carcinoma virtually teratomas . On contrary , ITGCN intensely express PTEN , indicate loss PTEN expression early event testicular tumor development , associate progression disease . Previously , show , testicular germ cell tumor cell line low activity proteins involve nuclear excision repair ( NER ) assume low NER activity relate favorable response testis tumor cisplatin-based chemotherapy . Gemcitabine carboplatin show activity refractory TGCTs . Recently , maximal tolerate dose Veliparib ( ABT-888 ) gemcitabine carboplatin establish . Based aforementioned data , strong rationale inhibit PARP TGCT . Inactivation PARP Veliparib along defect homologous recombination due PTEN inactivation GCTs low activity nucleotide excision repair system dramatically increase antitumor effect gemcitabine carboplatin patient progress relapse germ cell cancer .</detailed_description>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Men age 18 year old 3 . ECOG performance status : 01 , 4 . Histologically confirm extracranial primary germ cell cancer , seminoma , nonseminoma 5 . Rising serum marker ( i.e. , alphafetoprotein human chorionic gonadotropin ) sequential measurement biopsyproven unresectable germ cell cancer 6 . Refractory GCTs e.g . patient relapse highdose chemotherapy patient non fit enough highdose chemotherapy 7 . Primary mediastinal GCTs first relapse 8 . Patient 's disease must amenable cure either surgery chemotherapy opinion investigator , 9 . Measurable disease radiologically 10 . Adequate hematologic function define ANC &gt; 1500/mm3 , platelet count &gt; 100 000/mm3 hemoglobin level &gt; 9g/dl . 11 . Adequate liver function define total bilirubin level &lt; 1.5 ULN , ALT , AST &lt; 3 ULN &lt; 5 case liver metastasis . For subject Gilbert 's syndrome bilirubin &gt; 1.5 Ã— ULN allow symptom compromise liver function present 12 . Adequate renal function : measure calculate ( Cockcroft formula ) creatinine clearance &gt; 50 ml/min . Cockcroft formula : CLcr = [ ( 140age ) x weight ( Kg ) ] / [ 72 x creatinine ( mg/dl ) ] 13 . At least 4 week must elapse since last radiotherapy and/or chemotherapy study entry , 14 . At least 4 week must elapse since last major surgery 15 . Complete recovery prior surgery , and/or reduction adverse event previous systemic therapy radiotherapy grade 1 , 16 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 1 . Patients fit inclusion criterion 2 . Other prior malignancy except successfully treat nonmelanoma skin cancer 3 . Prior PARP1 inhibitor 4 . Other concurrent approve investigational anticancer treatment , include surgery , radiotherapy , chemotherapy , biologicresponse modifier , hormone therapy , immunotherapy 5 . Female patient 6 . Patients infected Human Immunodeficiency Virus ( HIV ) 7 . Patients severe acute chronic medical condition , laboratory abnormality would impair , judgment investigator , excess risk associate study treatment , , judgment investigator , would make patient inappropriate entry study 8 . Inability oral intake , drug absorption ( e.g . malabsorption syndrome ) 9 . Hypersensitivity compound drug 10 . Sexually active men use highly effective birth control partner woman childbearing potential 11 . Patients history current CNS metastasis 12 . Patients history seizure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple relapsed/refractory testicular germ cell tumor</keyword>
	<keyword>PARP inhibition</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
</DOC>